Vical finds way out of R&D woes via reverse merger with dermatology biotech Brickell

Vical finds way out of R&D woes via reverse merger with dermatology biotech Brickell

Source: 
Endpoints
snippet: 

Months after burying its third and final clinical program, Vical has turned to a reverse merger with Brickell Biotech to put an end to its misery. The new company — in which Vical investors will retain a 40% ownership — will operate under Brickell’s name and agenda.